These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11280930)

  • 1. Vaccine trials.
    Farrington CP; Miller E
    Mol Biotechnol; 2001 Jan; 17(1):43-58. PubMed ID: 11280930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine efficacy determination.
    Broome CV
    NIPH Ann; 1991 Dec; 14(2):219-21; discussion 222-4. PubMed ID: 1812435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological factors in clinical trial design.
    Wassilak S
    Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.
    Black S
    Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical considerations for noninferiority/equivalence trials in vaccine development.
    Wang WW; Mehrotra DV; Chan IS; Heyse JF
    J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
    Huang Y; Gilbert PB; Fu R; Janes H
    Biostatistics; 2017 Apr; 18(2):230-243. PubMed ID: 27649715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in the design and implementation of vaccine trials in less developed countries.
    Deen JL; Clemens JD
    Nat Rev Drug Discov; 2006 Nov; 5(11):932-40. PubMed ID: 17080029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating vaccine safety before and after licensure.
    Clemens J
    Bull World Health Organ; 2000; 78(2):218-9. PubMed ID: 10743289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential generalized likelihood ratio tests for vaccine safety evaluation.
    Shih MC; Lai TL; Heyse JF; Chen J
    Stat Med; 2010 Nov; 29(26):2698-708. PubMed ID: 20799244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
    Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF
    Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group
    AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial.
    Bugarini R; Casula D; Groth N; Lattanzi M; Holmes S; Podda A
    Vaccine; 2010 Oct; 28(46):7401-6. PubMed ID: 20850533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the effect of HIV vaccination on infectiousness.
    Rida WN
    Stat Med; 1996 Nov 15-30; 15(21-22):2393-404; discussion 2405-12. PubMed ID: 8931209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multistage designs for vaccine safety studies.
    Dragalin V; Fedorov V
    J Biopharm Stat; 2006; 16(4):539-53. PubMed ID: 16892912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine clinical trials--a statistical primer.
    Mehrotra DV
    J Biopharm Stat; 2006; 16(4):403-14. PubMed ID: 16892903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and estimation for evaluating principal surrogate markers in vaccine trials.
    Huang Y; Gilbert PB; Wolfson J
    Biometrics; 2013 Jun; 69(2):301-9. PubMed ID: 23409839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the safety of combination vaccines.
    Ellenberg SS
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S319-22. PubMed ID: 11709766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.